Akero Therapeutics Investor Relations Material
Latest events
Study Result
Akero Therapeutics
Q1 2025
12 May, 2025
Q4 2024
28 Feb, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Akero Therapeutics Inc
Access all reports
Akero Therapeutics Inc. is a clinical-stage biopharmaceutical company primarily engaged in developing innovative treatments for serious metabolic diseases with significant unmet medical needs. The company's primary focus is on its lead product candidate, efruxifermin (EFX), which is in clinical trials for the treatment of non-alcoholic steatohepatitis (NASH), a progressive liver disease characterized by fat accumulation and inflammation in the liver. The company is headquartered in South San Francisco, California, and its shares are listed on the NASDAQ.
Latest articles
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
)
D. E. Shaw & Co: Inside the Quiet Giant of Quant Finance
A deep dive into D. E. Shaw's evolution from a $28M quant startup to a $65B hedge fund giant, built on research, computing, and quiet consistency.
2 Jul 2025
)
Pershing Square Capital Management: Conviction, Reinvention, and Contrarian Investing
Pershing Square Capital Management has grown into a top-tier hedge fund through reinvention, conviction, and focus on long-term value creation.
2 Jul 2025
Ticker symbol
AKRO
Country
🇺🇸 United States